Jakarta, Indonesia – January 27, 2021 – Kalbe Genexine Biologics (“KGBio” or “the Company”), a leading integrate biologics holding company focused on the in-licensing, clinical development,  and manufacturing of novel biologicals and biosimilar molecules, today announced that General Atlantic, a leading global growth equity firm, will invest US$55 million in primary capital in the Company. The investment will support KGBio's ongoing clinical development and commercialization needs, asset acquisition plan, and production capacity expansion efforts. 

Jakarta, January 16, 2021 – PT Kalbe Farma Tbk (Kalbe) through the One Onco division along with the Indonesian Cancer Care Community (ICCC) and the Indonesian Cancer Foundation (YKI) of West Java, and is also supported by KALGen INNOLAB; conducted an online education event to commemorate the Cervical Cancer Awareness Month 2021 through a webinar themed 'Time for Cervical Cancer Screening' with speaker dr. Gatot N.A. Winarno, Sp.OG(K), M.Kes. 

Jakarta, 9 January 2021 – PT Kalbe Farma Tbk (Kalbe) today through one of its subsidiaries, Kalgen Innolab, launched the newest genetic testing methods, FitGENME; which consist of 2 types of tests; FitGENME Diet and FitGENME Sports. FitGENME Diet is a genetic test that can analyze variations in the DNA that are associated with the metabolism of a nutrient. While FitGENME Sports is a genetic test that can analyze variations in DNA that are associated with the metabolism of the body against certain types of sports. 

Jakarta, 30 December 2020 - PT Kalbe Farma Tbk (Kalbe) through its subsidiary PT Kalbe-Genexine Biologics (KGBio) today has received approval for a clinical trial (PPUK) from the Food and Drug Administration of the Republic of Indonesia (BPOM) to carry out Phase 2 clinical trials of the drug GX-17, which is an immunotherapeutic drug that will be developed as a treatment for COVID-19 patients. BPOM has issued approval to KGBio to conduct a phase-2 clinical trial based on safety and effectiveness data from a previous study conducted by Genexine with IMAB in South Korea.

Jakarta, December 23, 2020 – PT Kalbe Farma Tbk (“Kalbe” or the “Company”) held the Company's Extraordinary General Meeting of Shareholders (“EGMS”) which was held on 23 December 2020 at the Kalbe Business Innovation Center Building, Pulogadung, Jakarta.